Optimize Financial’s Soleno Therapeutics SLNO Stock Holding History

Optimize Financial’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,169	Closed	-$374K	–	302
2026 Q1	$374K	Buy	+11,169	New	+$438K	0.18%	208
2025 Q3	–	Sell	-3,812	Closed	-$319K	–	417
2025 Q2	$319K	Sell	3,812 -26	-0.7%	-$1.95K	0.2%	155
2025 Q1	$274K	Buy	+3,838	New	+$187K	0.1%	149

Optimize Financial's SLNO Position: Q2 2026 in Review

Optimize Financial sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 11,169 shares — an estimated $374K sold.

Optimize Financial first reported a position in SLNO in Q1 2025 and held it in 3 quarters. The position peaked at $374K in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Optimize Financial reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Optimize Financial sold 11,169 Soleno Therapeutics shares in Q2 2026, an estimated $374K.
Optimize Financial first reported a position in Soleno Therapeutics in Q1 2025 and held it in 3 quarters.
Optimize Financial's Soleno Therapeutics position peaked at $374K in Q1 2026.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Optimize Financial's 13F filing for Q2 2026, filed 27 Aug 2026.